Retirement comes with a certain rhythm of decisions, and most people make them once and move on. The Medicare drug plan question tends to fall into that category. You turn 65, something arrives in the mail, you pick a plan, and you forget about it. For years, that approach worked well enough. But 2026 is a genuinely different year for Medicare Part D, and the autopilot approach carries more financial risk than most retirees realize.
Several overlapping changes are now in effect simultaneously. Congress rewrote the economic rules of prescription drug coverage. Bundled Medicare Advantage plans are competing more aggressively than ever. And income-based surcharges are eating deeper into retirement budgets for those who earned well before stepping away from work. The result is a medicare drug plan 2026 decision that looks different for nearly every type of retiree, depending on how many prescriptions they take, how much they earned two years ago, and what kind of coverage they already hold.
None of this means standalone Part D is a bad deal. For many people, it remains exactly the right choice. But picking the right path requires understanding three specific situations where the default choice either costs more than it should or misses a better option entirely.
1. The Cheapest Compliant Plan Often Wins – Especially If You Take Few Drugs
Most people shopping for prescription drug coverage assume more coverage means better value. With Part D, that logic frequently breaks down for retirees who take few or no daily medications.
As of early 2026, more than 56 million people are enrolled in Medicare Part D, according to the Centers for Medicare and Medicaid Services, with more than half in Medicare Advantage drug plans (MA-PDs) and the rest in standalone prescription drug plans (PDPs). That enrollment spread matters because it reflects a growing awareness that a one-size-fits-all standalone plan is often not the optimal financial choice. This year, the average original Medicare beneficiary has access to just 14 standalone drug plans, the fewest since the Part D program launched in 2006. Fewer options mean it pays to evaluate each one carefully rather than defaulting to a familiar name.
For standalone Part D prescription drug plans, the CMS announced that the average total premium is projected to fall from $38.31 in 2025 to $34.50 in 2026. That decline is welcome. But premium is only one piece of the cost equation. The average monthly enrollment-weighted premium for non-group standalone PDPs fell from $39 to $36 between February 2025 and February 2026, partly reflecting shifts from higher-premium to lower-premium plans. For a retiree who fills one or two cheap generics per month, a richer formulary delivering access to brand-name drugs simply isn’t worth the extra premium. The practical takeaway: pull up the plan finder at Medicare.gov, enter your exact drug list, and sort by estimated annual cost, not by premium alone.
One more thing to understand before settling on a plan: cash-discount tools like GoodRx work differently in 2026 than they used to. Once you spend $2,100 on covered medications under your Part D plan, your cost is $0 for the rest of the year. But GoodRx purchases do not count toward this cap. If you spend money using GoodRx coupons, that spending is invisible to Medicare and does not help you reach the threshold. For retirees on expensive brand-name drugs, running every purchase through the Part D plan is often the smarter move, even if a coupon app shows a marginally lower sticker price on a given day. For inexpensive generics that sit well below your deductible, cash pricing can still save you money without meaningfully delaying your progress toward the cap.
2. A Medicare Advantage Drug Plan May Already Make Standalone Coverage Redundant
The second reason to pause before enrolling in a standalone Part D plan is simpler: you may not need one at all.
Retirees who enroll in a Medicare Advantage plan (also called Part C) with built-in prescription drug coverage, known as an MA-PD, get their hospital, medical, and drug benefits bundled into a single plan. There is no separate Part D enrollment to manage, no separate premium, and no separate formulary to decode. According to the CMS press release cited above, the average monthly plan premium across all Medicare Advantage plans is estimated to decrease from $16.40 in 2025 to $14.00 in 2026. The drug component specifically runs even lower. After applying MA rebates, the average total premium for Part D coverage bundled into MA plans is projected to fall to $11.50 in 2026.
By contrast, beneficiaries in each state will have a choice of between 8 and 12 Medicare Part D standalone prescription drug plans, according to the Medicare Rights Center. That’s a narrowing field. Perhaps most striking for cost-conscious retirees: a 2026 KFF analysis found that two-thirds of all Medicare Advantage drug plans charge no premium beyond what enrollees already pay for Medicare Part B, meaning drug coverage effectively comes at no additional monthly cost.
The tradeoff is real and worth naming clearly. Medicare Advantage plans use provider networks, meaning your choice of doctors and hospitals may be restricted. Prior authorization requirements, where the plan must approve certain drugs or procedures before covering them, are more common in MA-PDs than in traditional Medicare. For retirees who travel frequently or want the freedom to see any Medicare-approved provider nationwide, Original Medicare combined with a standalone Part D plan still makes sense. But for healthy retirees who primarily use in-network providers and want to simplify their coverage into a single monthly bill, an MA-PD removes the standalone Part D decision entirely. The key question to ask is not “which plan is cheapest?” but “which structure fits how I actually use healthcare?”
If you already have an MA-PD and are happy with your network, you should also keep in mind that plans adjust their formularies, the list of covered drugs, and cost-sharing amounts every year. A plan that was optimal last year may not cover your current medications at the same tier. Reviewing coverage during Medicare’s open enrollment period – which runs from October 15 to December 7 – is worth putting on the calendar every fall.
3. IRMAA Surcharges Can Make Standalone Part D Far More Expensive Than It Appears
The third reason to reconsider the default enrollment decision applies most directly to retirees with higher incomes, and it catches many people off guard precisely because the bill arrives before they fully understand how it’s calculated.
IRMAA stands for Income-Related Monthly Adjustment Amount. It’s an extra charge added on top of your Medicare premiums when your income exceeds certain thresholds. Most people know it applies to Medicare Part B. Fewer realize it hits Part D as well. According to Kiplinger’s 2026 IRMAA guide, the IRMAA surcharges for Part D in 2026 range from $14.50 to $91.00 per month, or $174 to $1,092 annually. That’s a meaningful addition to your premium, and it compounds because in 2026, if your 2024 adjusted gross income is above $109,000 as a single filer or $218,000 as a married couple filing jointly, you will pay that surcharge on top of your Part D plan premium.
The two-year look-back is what surprises most retirees. IRMAA is based on your tax returns from two years prior, meaning your 2026 liability is determined by your 2024 income. Someone who had a high-income year in 2024 due to a property sale, a Roth conversion, or a retirement distribution may now be paying IRMAA in 2026 even though their current income has dropped significantly. The good news: you can appeal this. If your income has dropped materially since the base year, Medicare allows you to request a reconsideration using a more recent tax return.
What does this mean practically for plan selection? A professor of health care policy at Harvard Medical School, cited in a Newsweek report on Medicare plan comparison, noted that “the most important thing for Medicare beneficiaries to do is comparison shop and seek assistance to understand their options,” observing that beneficiaries often remain in plans that no longer serve them well. For high earners, the specific plan chosen matters less than you might expect, because the IRMAA surcharge is added on top of whichever plan you select. Choosing the lowest-premium compliant plan in your area limits the total damage, since you cannot avoid the surcharge by picking a pricier plan; you only add to the burden.
This dynamic makes employer-sponsored retiree drug coverage especially worth protecting if you have it. If you choose not to join a Medicare drug plan, you need creditable drug coverage to avoid the Part D late enrollment penalty. Creditable coverage is coverage that provides the same value as Medicare drug coverage, and if you’re unsure whether your retiree drug plan qualifies, your plan is legally required to tell you. The late enrollment penalty is not a one-time fee. According to the National Council on Aging, in most cases the Medicare Part D penalty lasts for as long as you have Medicare drug coverage, even if you switch plans. And the penalty applies for each month of delay, calculated as 1% of the national base beneficiary premium per month without creditable coverage.
Read More: 7 Ways Trump Is Reshaping Social Security Right Now
What to Do Before Your Next Enrollment Window
The three situations described above point toward a single broader truth: Medicare drug coverage rewards people who review their options annually and penalizes those who don’t.
Negotiated prices for 10 drugs selected by Medicare took effect January 1, 2026. According to a CMS fact sheet on the negotiated prices, those prices represent a minimum 38% discount from 2023 list prices, and when they go into effect, people enrolled in Medicare prescription drug coverage are estimated to save roughly $1.5 billion annually. Drugs like Eliquis, Jardiance, and Januvia are now subject to government-set maximum fair prices for the first time. But accessing those savings requires being enrolled in a plan that covers those drugs, and reviewing your formulary to make sure your plan’s tier placement hasn’t changed.
The most practical steps to take now: pull your current drug list, enter it into the Medicare Plan Finder tool at Medicare.gov, and compare your total estimated annual cost – premium plus deductible plus expected copays – across every available plan in your zip code. If you’re in a high income bracket, factor in the IRMAA surcharge. If you have employer retiree drug coverage, verify with your benefits administrator that it still qualifies as creditable. And if you’re weighing Original Medicare against Medicare Advantage, think about how often you travel, whether your doctors are in-network, and how much the bundled structure simplifies your life. The decision is reversible during open enrollment each year, which means there’s no reason to stay locked into a plan that no longer fits.
Disclaimer: This information is not intended to be a substitute for professional financial advice, investment advice, tax advice, or legal advice, and is provided for informational purposes only. Always seek the guidance of a qualified financial advisor, accountant, or other licensed professional regarding your personal financial situation or investment decisions. Do not make financial, investment, or tax decisions based solely on information presented here. Past performance is not indicative of future results, and all investments carry risk, including the potential loss of principal.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: 5 Medicare Changes for 2027 That Will Directly Affect Your Coverage and Costs